Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.

Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1. Oncotarget (2015) 0.75

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89

Melanoma biology and new targeted therapy. Nature (2007) 10.71

Management of cutaneous melanoma. N Engl J Med (2004) 9.52

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res (2006) 3.32

Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol (2008) 3.16

Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89

NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer (2011) 2.69

KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov (2012) 2.56

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 2.41

Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res (2002) 2.18

Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg (2007) 1.96

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res (2011) 1.87

Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res (2010) 1.78

Main roads to melanoma. J Transl Med (2009) 1.67

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One (2007) 1.65

Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol (2007) 1.63

Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn (2012) 1.59

BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One (2011) 1.40

A phase 2 trial of dasatinib in advanced melanoma. Cancer (2010) 1.40

EGFR in melanoma: clinical significance and potential therapeutic target. J Cutan Pathol (2011) 1.32

Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother (2012) 1.18

Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res (2014) 1.10

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol (2009) 1.08

Surgical management of melanoma lung metastasis: an analysis of survival outcomes in 292 consecutive patients. Ann Surg Oncol (2012) 1.07

Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Spec Pharm (2014) 1.07

Association of activated c-Met with NRAS-mutated human melanomas. Int J Cancer (2012) 1.06

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget (2015) 1.00

MEK targeting in N-RAS mutated metastatic melanoma. Mol Cancer (2014) 0.98

Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. J Invest Dermatol (2014) 0.96

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer (2014) 0.93

EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer (2007) 0.92

Survival after pulmonary metastasectomy in patients with malignant melanoma. Thorac Cardiovasc Surg (2011) 0.88

Novel therapeutics for the treatment of metastatic melanoma. Future Oncol (2009) 0.86

Pulmonary metastasectomy for melanoma. J Thorac Oncol (2010) 0.85

Pulmonary metastasectomy for malignant melanoma: prognostic factors for long-term survival. Melanoma Res (2013) 0.85

Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia (2001) 0.81

Diagnosis and treatment of KIT-mutant metastatic melanoma. J Clin Oncol (2013) 0.79

Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. Br J Cancer (2014) 0.78

Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview. Toxicon (2015) 0.76